180 related articles for article (PubMed ID: 29133035)
1. Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells.
Ramisetti SR; Pandey MK; Lee SY; Karelia D; Narayan S; Amin S; Sharma AK
Eur J Med Chem; 2018 Jan; 143():1919-1930. PubMed ID: 29133035
[TBL] [Abstract][Full Text] [Related]
2. Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF
Aldaghi SA; Jalal R
Chem Res Toxicol; 2019 Apr; 32(4):645-658. PubMed ID: 30829029
[TBL] [Abstract][Full Text] [Related]
3. A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma.
Babu A; Laila SP; Fernandez A
Anticancer Agents Med Chem; 2021; 21(15):2066-2074. PubMed ID: 33372883
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAF
Ali EMH; Abdel-Maksoud MS; Ammar UM; Mersal KI; Ho Yoo K; Jooryeong P; Oh CH
Bioorg Chem; 2021 Jan; 106():104508. PubMed ID: 33280830
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.
Lu C; Tang K; Li Y; Li P; Lin Z; Yin D; Chen X; Huang H
Eur J Med Chem; 2014 Apr; 77():351-60. PubMed ID: 24675135
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
[TBL] [Abstract][Full Text] [Related]
11. NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
Kaoud TS; Mohassab AM; Hassan HA; Yan C; Van Ravenstein SX; Abdelhamid D; Dalby KN; Abdel-Aziz M
Eur J Med Chem; 2020 Jan; 186():111885. PubMed ID: 31784187
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.
Li QS; Li CY; Lu X; Zhang H; Zhu HL
Eur J Med Chem; 2012 Apr; 50():288-95. PubMed ID: 22361686
[TBL] [Abstract][Full Text] [Related]
13. Light-controlled inhibition of BRAFV600E kinase.
Hoorens MWH; Ourailidou ME; Rodat T; van der Wouden PE; Kobauri P; Kriegs M; Peifer C; Feringa BL; Dekker FJ; Szymanski W
Eur J Med Chem; 2019 Oct; 179():133-146. PubMed ID: 31252305
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIα and Akt pathway inhibitor, and evaluation of its anti-melanoma activity.
Karelia DN; Sk UH; Singh P; Gowda ASP; Pandey MK; Ramisetti SR; Amin S; Sharma AK
Eur J Med Chem; 2017 Jul; 135():282-295. PubMed ID: 28458134
[TBL] [Abstract][Full Text] [Related]
16. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF
Li HL; Su MM; Xu YJ; Xu C; Yang YS; Zhu HL
Eur J Med Chem; 2018 Jul; 155():725-735. PubMed ID: 29940463
[TBL] [Abstract][Full Text] [Related]
17. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
18. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
Roy T; Boateng ST; Banang-Mbeumi S; Singh PK; Basnet P; Chamcheu RN; Ladu F; Chauvin I; Spiegelman VS; Hill RA; Kousoulas KG; Nagalo BM; Walker AL; Fotie J; Murru S; Sechi M; Chamcheu JC
Bioorg Chem; 2021 Feb; 107():104595. PubMed ID: 33450548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
